FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379282832> ?p ?o ?g. }

• W4379282832 endingPage "4067" @default.
• W4379282832 startingPage "4067" @default.
• W4379282832 abstract "4067 Background: The phase 3 PRODIGY study compared neoadjuvant docetaxel, oxaliplatin and S-1 (DOS) chemotherapy followed by surgery followed by adjuvant S-1 with surgery followed by adjuvant S-1 for Korean patients with resectable locally advanced gastric cancer (LAGC) (Kang et al. J Clin Oncol. 2021). The planned analysis of the primary endpoint of PRODIGY showed that the addition of neoadjuvant DOS to surgery and adjuvant S-1 improved progression-free survival (PFS). We herein report the long-term follow-up outcomes, including overall survival (OS), from this trial. Methods: Patients with histologically confirmed primary gastric or gastroesophageal junction adenocarcinoma with clinical T2-3N+ or T4Nany disease were enrolled from 18 Korean study sites. Patients were randomly assigned to D2 surgery followed by adjuvant S-1 (40–60 mg orally twice a day, days 1–28 q6w for eight cycles; SC group) or neoadjuvant DOS (docetaxel 50 mg/m 2 , oxaliplatin 100 mg/m 2 intravenously day 1, S-1 40 mg/m 2 orally twice a day, days 1–14 q3w for three cycles) before D2 surgery, followed by adjuvant S-1 (CSC group). The primary endpoint was PFS. OS was the secondary endpoint. This analysis presents the final assessment of the outcomes after 5 years. Results: A total of 266 and 264 patients were randomly assigned to the CSC and SC arms, respectively, among which 238 and 246 patients were treated and included in the full analysis set. As of the data cut-off date (SEP-2022), the median follow-up duration of the surviving patients was 99.5 months (range, 68.6–127.7 months). As compared to SC, CSC significantly increased the OS (adjusted hazard ratio, 0.72; 95% CI, 0.54 to 0.97; stratified log-rank P=0.028) with a 5-year OS rate of 66.8% and 63.0% for the CSC and SC arms, respectively. CSC also significantly improved the PFS (adjusted hazard ratio, 0.71; 95% CI, 0.53 to 0.94; stratified log-rank P=0.019) with a 5-year PFS rate of 60.6% and 56.9% for the CSC and SC arms, respectively. Conclusions: The addition of neoadjuvant docetaxel, oxaliplatin and S-1 (DOS) chemotherapy, as part of perioperative chemotherapy, to surgery and adjuvant S-1 prolonged the OS and PFS of Asian patients with LAGC relative to patients treated with surgery and adjuvant S-1 alone. Neoadjuvant DOS chemotherapy should be considered one of the standard treatment options for patients with LAGC in Asia. Clinical trial information: NCT01515748 ." @default.
• W4379282832 created "2023-06-05" @default.
• W4379282832 creator A5005925636 @default.
• W4379282832 creator A5023746600 @default.
• W4379282832 creator A5024676627 @default.
• W4379282832 creator A5024828401 @default.
• W4379282832 creator A5034764661 @default.
• W4379282832 creator A5038041478 @default.
• W4379282832 creator A5053847518 @default.
• W4379282832 creator A5057610578 @default.
• W4379282832 creator A5061052298 @default.
• W4379282832 creator A5062071958 @default.
• W4379282832 creator A5074290142 @default.
• W4379282832 creator A5076132049 @default.
• W4379282832 creator A5077673067 @default.
• W4379282832 creator A5083870771 @default.
• W4379282832 creator A5084870834 @default.
• W4379282832 creator A5085952795 @default.
• W4379282832 date "2023-06-01" @default.
• W4379282832 modified "2023-09-25" @default.
• W4379282832 title "Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: Final survival outcomes of the randomized phase 3 PRODIGY trial." @default.
• W4379282832 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.4067" @default.
• W4379282832 hasPublicationYear "2023" @default.
• W4379282832 type Work @default.
• W4379282832 citedByCount "0" @default.
• W4379282832 crossrefType "journal-article" @default.
• W4379282832 hasAuthorship W4379282832A5005925636 @default.
• W4379282832 hasAuthorship W4379282832A5023746600 @default.
• W4379282832 hasAuthorship W4379282832A5024676627 @default.
• W4379282832 hasAuthorship W4379282832A5024828401 @default.
• W4379282832 hasAuthorship W4379282832A5034764661 @default.
• W4379282832 hasAuthorship W4379282832A5038041478 @default.
• W4379282832 hasAuthorship W4379282832A5053847518 @default.
• W4379282832 hasAuthorship W4379282832A5057610578 @default.
• W4379282832 hasAuthorship W4379282832A5061052298 @default.
• W4379282832 hasAuthorship W4379282832A5062071958 @default.
• W4379282832 hasAuthorship W4379282832A5074290142 @default.
• W4379282832 hasAuthorship W4379282832A5076132049 @default.
• W4379282832 hasAuthorship W4379282832A5077673067 @default.
• W4379282832 hasAuthorship W4379282832A5083870771 @default.
• W4379282832 hasAuthorship W4379282832A5084870834 @default.
• W4379282832 hasAuthorship W4379282832A5085952795 @default.
• W4379282832 hasConcept C121608353 @default.
• W4379282832 hasConcept C126322002 @default.
• W4379282832 hasConcept C141071460 @default.
• W4379282832 hasConcept C143998085 @default.
• W4379282832 hasConcept C168563851 @default.
• W4379282832 hasConcept C203092338 @default.
• W4379282832 hasConcept C2776694085 @default.
• W4379282832 hasConcept C2777863537 @default.
• W4379282832 hasConcept C2778292576 @default.
• W4379282832 hasConcept C2780962732 @default.
• W4379282832 hasConcept C2781190966 @default.
• W4379282832 hasConcept C31760486 @default.
• W4379282832 hasConcept C526805850 @default.
• W4379282832 hasConcept C530470458 @default.
• W4379282832 hasConcept C71924100 @default.
• W4379282832 hasConceptScore W4379282832C121608353 @default.
• W4379282832 hasConceptScore W4379282832C126322002 @default.
• W4379282832 hasConceptScore W4379282832C141071460 @default.
• W4379282832 hasConceptScore W4379282832C143998085 @default.
• W4379282832 hasConceptScore W4379282832C168563851 @default.
• W4379282832 hasConceptScore W4379282832C203092338 @default.
• W4379282832 hasConceptScore W4379282832C2776694085 @default.
• W4379282832 hasConceptScore W4379282832C2777863537 @default.
• W4379282832 hasConceptScore W4379282832C2778292576 @default.
• W4379282832 hasConceptScore W4379282832C2780962732 @default.
• W4379282832 hasConceptScore W4379282832C2781190966 @default.
• W4379282832 hasConceptScore W4379282832C31760486 @default.
• W4379282832 hasConceptScore W4379282832C526805850 @default.
• W4379282832 hasConceptScore W4379282832C530470458 @default.
• W4379282832 hasConceptScore W4379282832C71924100 @default.
• W4379282832 hasIssue "16_suppl" @default.
• W4379282832 hasLocation W43792828321 @default.
• W4379282832 hasOpenAccess W4379282832 @default.
• W4379282832 hasPrimaryLocation W43792828321 @default.
• W4379282832 hasRelatedWork W122589447 @default.
• W4379282832 hasRelatedWork W1976599095 @default.
• W4379282832 hasRelatedWork W2124996540 @default.
• W4379282832 hasRelatedWork W2149964424 @default.
• W4379282832 hasRelatedWork W2234542209 @default.
• W4379282832 hasRelatedWork W2257017276 @default.
• W4379282832 hasRelatedWork W2407419195 @default.
• W4379282832 hasRelatedWork W3158992533 @default.
• W4379282832 hasRelatedWork W3211796712 @default.
• W4379282832 hasRelatedWork W4379282832 @default.
• W4379282832 hasVolume "41" @default.
• W4379282832 isParatext "false" @default.
• W4379282832 isRetracted "false" @default.
• W4379282832 workType "article" @default.